UroGen Q2 2020 Earnings Report
Key Takeaways
UroGen Pharma reported net product sales of Jelmyto of approximately $371,500 for the second quarter ended June 30, 2020. The company's cash, cash equivalents and marketable securities totaled $151.6 million as of June 30, 2020.
Received U.S. FDA Approval of Jelmyto, the First and Only Non-Surgical Treatment for Patients with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC)
Successfully Commenced Launch of Jelmyto on June 1st as Planned; Initial Commercial Performance Demonstrates Strong Execution
Announced Positive Complete Response and Durability Data of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
On Track to Commence Pivotal Phase 3 Trial by Year End
UroGen
UroGen
UroGen Revenue by Segment
Forward Guidance
UroGen adjusted expense guidance down for 2020, driven by change in estimated non-cash share-based compensation expense for 2020. UroGen now expects 2020 total operating expenses in the range of $143 to $153 million, including non-cash share-based compensation expense of $30 to $34 million, subject to market conditions.